Flyer

International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 49
  • Journal CiteScore: 11.20
  • Journal Impact Factor: 8.24
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

- (2013) Volume 5, Issue 2

Rubia cordifolia Overview: A New Approach to Treat Cardiac Disorders

Pankaj Bhatt*, A. S. Kushwah
Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, BELA, Ropar (Punjab), 140111, India
Corresponding Author: Pankaj Bhatt* M. Pharm (Student) Department of Pharmacology ASBASJSM College of Pharmacy, BELA, Ropar (Punjab), 140111, India E. mail: pankaj.bhatt001@gmail.com
Received:12 March 2013 Accepted: 16 April 2013
Citation: Pankaj Bhatt*, A. S. Kushwah “Rubia cordifolia Overview: A New Approach to Treat Cardiac Disorders” Int. J. Drug Dev. & Res., April-June 2013,
5(2): 47-54.doi: doi number
Copyright: © 2013 IJDDR, Pankaj Bhatt et al. This is an open access paper distributed under the copyright agreement with Serials Publication, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Related article at Pubmed, Scholar Google
Visit for more related articles at International Journal of Drug Development and Research

Abstract

Ethno-botanical and ethno-pharmacological studies of Rubia cordifolia continue to attract investigators for research work globally. Rubia cordifolia commonly known as Manjistha or Indian madder is an important medicinal plant growing up to 3500 meters height. Rubiae Radix (dried roots of Rubia cordifolia, Rubiaceae) is a rich source of anthraquinones responsible for its traditional, phytochemical and pharmacological activities. Today clinical investigations of herbal formulations and their market preparations, both are on demanding because of better safety and efficacy without or minimal side effects. This review summarizes the concept of finding new approach to treat cardiac disorders on the basis of previous reports of this plant.c

Keywords

Rubia cordifolia, Traditional uses, Phytochemical studies, Pharmacological actions, Recent activities, Cardioprotective approach.

INTRODUCTION

Ayurvedic materia medica mentioned Manjistha as detoxifying herb removing “ama/toxin” from the blood. Rubia denotes ‘red’ as their internal use imparts red color to breast milk and urine1. Roots of this plant having high medicinal value and are recognized as official2. In the ethnobotanical claims, roots of Rubia cordifolia mentioned for the treatment of jaundice used by the folk tribes of West Bengal and Uttaranchal. Manjistha stem describes as cure for snake bite and scorpion sting. It is also effective on non healing diabetic foot ulcer3. Manjistha having cooling effect in the body and therefore, traditionally used for chronic pyrexia and puerperal fever. It is a popular remedy for the relief of heat and itching in eczema, psoriasis, herpes, scabies and also reported successful in treatment of vitiligo when given with honey4. Manjistha has been reported for the presence of glycosides, saponins, anthraquinones, tannins, hexapeptides, quinones, triterpenoids5. Literature describes the beneficial effects of Rubia cordifolia in treatment of number of ailments including alzheimer, diabetes, cancer, acne, inflammation, allergy, enterocolitis, bacterial and viral infection. Other reported activities are immunomodulator, analgesic, diuretic, gastroprotective, hepatoprotective and nephroprotective. Rubia cordifolia show potent antioxidant activity against lead nitrate and radiation induced toxicity6, 7. Rubia cordifolia has been evaluated for its wound healing activity8. The leaves of this plant also studied for its antiviral and in-vitro free radical scavenging activity9. Apart from its medicinal value, Manjistha has also been used as natural food colorants and natural dyes. The coloring pigments present in the roots are purpurin and munjistin in major amounts. Madder root extract has investigated for its dying characteristics and yielded beautiful orange red to scarlet shades when applied onto the woolen yarn10.

TRADITIONAL USES:

Manjistha is an ayurvedic herb that is mentioned in Charaka and Sushruta. Charaka has categorized it as varnya, jvarahara, vishaghna. Sushruta has mentioned it pittasamsamana. Traditional uses of manjistha mentioned in ayurvedic materia medica are following:
Ayurvedic pharmacopoeia of India therapeutically indicate it for Yoni roga (menstrual disorder), Kustha (skin disease), Sarpavisa (snake bite), Visarpa (herpes virus), Aksi roga (eye disease), Arsa (haemorrhoids), Bhagna (Fracture)11.
According to the ancient ayurvedic text, Bhava Prakash, Manjistha is able to bind with amavisha (free radicals) and garavisha (xenobiotics) toxins which cause inflammation, skin disease, ulcers, among other problems. Manjistha in Sanskrit also termed as Jingi (vibrational energy) which helps to reestablish the intelligence of the tissues. A balanced combination of soma (cooling) and agni (heat) found in Manjistha. Agni allows the herb to penetrate into the cellular level of tissues and Soma helps to soak up the toxins and neutralize them.

Ayurvedic preparations:

Manjistha is an important ingredient of many ayurvedic formulations and preparations; Mahamanjisthadi kvatha, Manjisthadi taila, Manjistha arka, Manjistha malahara, Manjistha phanta, Septilin syrup etc.
Mahamanjisthadi kvatha: The herbal supplement used as blood purifier, immunomodulator, promotes skin health and complexion.
Septilin syrup: A polyherbal preparation containing Rubia cordifolia as one of the ingredient, tried in 40 children suffering from various upper respiratory tract infections. Very good response was seen in 34 (85%) children. Incidence of recurrences was minimal12
Body Revival: It is an Indian herbal formulation having suspension of Aegle marmelos, Acorus calamus, Rubia cordifolia, Saussurea lappa, Blumea lacera, Rumex vasicarius, Curcumas melo, Symplocos racemosa and honey. Investigation showed that Body Revival potentiates cardioprotection against isoproterenol induced myocardial ischemia and ADP or collagen induced human platelet aggregation13.

PHYTOCHEMICAL STUDIES:

Rubia cordifolia (Manjistha) basically known for its anthraquinones and naphthohydroquinones phytochemical constituents14. The major phytoconstituents of Rubia cordifolia reported include Rubiadin15, Rubicordone A16, Rubiasins AC17, Rubiatriol (triterpenoid)18, 6-methoxygeniposidic acid an iridoid glycoside19 and two pentacyclic triterpenoid- Rubicoumaric acid and Rubifolic acid20. Mollugin, furomollugin, dehydro-alpha-lapchone are isolated from chloroform fraction21.
The primary chromophores present in Rubia cordifolia are alizarin, purpurin, pseudopurpurin xanthopurpurin, munjistin, rubiadin. All of the chromophores share the base 9,10-anthraquinone structure but with different functional groups at carbons 1-4 (Fig. A)22.
Four naphthoic acid esters namely rubilactone, 3'- carbomethoxy-4'-hydroxy-naphtho[1',2'-2,3]furan, dihydromollugin and 3-carbomethoxy-2(3'- hydroxy)isopentyl-1,4-naphthohydroquinone-1-Obeta- D-glucoside were isolated from the roots of Rubia cordifolia23.
Identification of aroma compounds in Rubiae Radix (dried roots of Rubia cordifolia) done by gas chromatography. As a result of 43 components, accounting for 91.5% of total oil detected, in which mollugin (19.6%), furomollugin (17.4%), eugenol (12.7%), (E)-anethole (10.6%), 4-tert-butyl-2-phenyl phenol (9.9%), menthol (2.7%) are the main components24.

Biomarkers:

PHARMACOLOGICAL ACTIONS

RECENT ACTIVITIES:

1. Antibacterial activity of ethanolic extract of Rubia cordifolia evaluated against ESBL (Extended Spectrum Beta-Lactamase) producing urinary E.coli infection. Isolation of different E.coli strains done from urine samples of patients and all the isolates tested for different antibiotics and screened for their ESBL production. Total 7 different ESBL producing E.coli obtained and tested against the ethanolic extract of Rubia cordifolia using Kirby Bauer method and found to be inhibited variably by the extract. The plant can be a potential candidate as alternative antibacterial agent to combat drug resistant organisms49.
2. Methanolic extract of Rubia cordifolia showing ameliorative effect in N-nitrosodiethylamineinduced hepatocellular carcinoma in rats. Mitochondrial enzymes and respiratory chain enzymes, which decreased in Nnitrosodiethylamine treated rats, increased significantly in Rubia cordifolia treated rats. The levels of hydroxyl radicals and lipid peroxidation also decreased. Histological analysis of liver confirmed the prevention of pathological changes caused by Nnitrosodiethylamine, which suggest that Rubia cordifolia may be developed as an effective chemotherapeutic agent50.
3. Psoriasis is skin disorder characterized by hyperproliferation and aberrant differentiation of epidermal keratinocytes. Ethyl acetate (EA) fraction of Radix Rubiae inhibits cell growth and promotes terminal differentiation in cultured human keratinocytes which strongly suggest its antipsoriatic activity. Evaluation is done by cornified envelope (CE) formation assay showed that EA fraction of Radix Rubiae significantly accentuated the CE formation, a well-recognized marker of terminal differentiation, in cultured HEK and HaCaT cells in a dose and time dependent manner51.
4. Methanolic extract of Rubia cordifolia induced typical apoptosis in HEp-2 (Human laryngeal carcinoma) cell line through the elevation of reactive oxygen species generation. Inhibition of cell proliferation and lactate dehydrogenase release increased in a time and dose-dependent manner. Apoptotic effect of Rubia cordifolia extract (30 mg/ml) on HEp-2 cells confirmed by fluorescent and transmission electron microscopy based on morphological and ultrastructural changes52.
5. Alizarin, a natural hydroxyanthraquinone derived from root of Rubia cordifolia evaluated as an osteotropic drug for treatment of bone tumors because of its high affinity to bone. Antitumor activity of alizarin investigated on human cell lines representative for bone metastases from prostate cancer, breast cancer and for three human osteosarcoma cell lines. Alizarin induced a dose-dependent inhibition of cell growth over time in osteosarcoma and breast cancer cell lines, whereas in prostate cancer cell line, it appeared to be cytotoxic only at higher concentration. Studies found that alizarin acted through the inhibition of ERK phosphorylation and cell cycle arrest in the Sphase53.

CARDIOPROTECTIVE APPROACH:

Rubia cordifolia role in supporting heart health is evidenced by traditional and reported activities which show that it act as potent blood purifier, antioxidant, diuretic, calcium channel blocker, antiplatelet, antidiabetic, antiinflammatory, antistress, immunomodulator etc. Rubia cordifolia known for its antioxidant, antiinflammatory and potent blood purifier activities can play an important role to detoxify ischemia induced free radical generation. Diuretic activity of Rubia cordifolia could be an alternative therapy in the management of congestive heart failure (CHF) for rapid mobilization of edema fluid. Antistress, diuretic and vasodilating properties of Manjistha can play an important role in the management of hypertension. Rubia cordifolia inhibits platelet aggregation induced by PAF (Platelet Activating Factor) potentiate its therapeutic role in coronary artery disease. Antihyperglycemic and antihyperlipidemic effects of Manjistha direct its medicinal role in diabetic cardiomyopathy and diabetic macrovascular disease. Rubia cordifolia exhibits spasmolytic activity similar to that of verapamil suggestive of presence of calcium channel blocker(s) like constituents in this plant54 and therefore, indicates its possibility to treat arrhythmias result from calcium overload in ischemia-reperfusion condition.

CONCLUSION:

Today prescription of combination therapy (hypolipidemic, diuretic, calcium channel blocker, vasodilator, antiplatelet) are common in patients with cardiac dysfunction. Chances of drug interaction and adverse effect arise with combination therapy. Rubia cordifolia an individual plant with multiple activities that is essential to support heart health could become a new approach in the management of cardiac disorders and therefore, need research work to isolate cardiac biomarkers from this plant.

Tables at a glance

Table icon Table icon Table icon Table icon
Table 1 Table 2 Table 3 Table 4
 

Figures at a glance

Figure 1
Figure A
 
6718

References

  1. McIntyre A. Monographs of Ayurvedic herbs commonly used in the treatment of children. Herbal treatment of children, 2005, pp 87-135.
  2. Deshkar N, Tilloo S, Pande VA. Comprehensive review of Rubiacordifolia Linn.Phamacognosy reviews. 2008; 2(3): 124-123.
  3. Ojha JK, Dwivedi KN, Chaurasiya AK. Effect of Rubiacordifolia on non healing diabetic foot ulcer. Nat. Sem. Trad. Med. Plants in Skin Care, CIMAP, Lucknow, 1994, pp 17.
  4. Gogte VVM. Ayurvedic pharmacology and therapeutic uses of medicinal plants.BharatiyaVidyaBhavan, Mumbai, 2000.
  5. Antarkar SS, Chinwalla T, Bhatt N. Antiinflammatory activity of Rubiacordifolia Linn. in rats. Indian J Pharmacol.1983; 15: 185-188.
  6. Lodia S, Kansala L. Antioxidant activity of Rubiacordifolia against lead toxicity. International Journal of Pharmaceutical Sciences and Research. 2012; 3(7): 2224-2232.
  7. Tripathi YB, Singh AV. Role of Rubiacordifolia Linn. in radiation protection. Indian Journal of Experimental Biology. 2007; 45(7): 620-625.
  8. Karodi R, Jadhav M, Rub R, Bafna A. Evaluation of the wound healing activity of a crude extract of Rubiacordifolia L. (Indian madder) in mice. Int J App Res Nat Pro. 2009; 2(2): 12-18.
  9. Prajapati SN, Parmar KA. Anti-viral and in-vitro free radical scavenging activity of leaves of Rubiacordifolia.International Journal of Phytomedicine.2011; 3: 98-107.
  10. Yusuf M, Shahid M, Khan MI, Khan SA, Khan MA, Mohammad F. Dying studies with henna and madder: A research on effect of tin(II) chloride mordant. Journal of Saudi chemical society (2012).
  11. The ayurvedic pharmacopoeia of India. Ministry of health and family welfare, Department of ISM&H, Govt. of India, New Delhi. 2001; Part-I &Vol-III: 112-124.
  12. Suryawanshi NM, Suryawanshi JN. Observations on septilin syrup in upper respiratory tract infections(URTIS), Probe, Vol. 29(1), pp 19-20.
  13. Sur TK, Auddy B, Bhattacharyya D. Effects of Indian herbal formulation body revival on human platelet aggregation and myocardial ischemia in rats. Journal of Chinese Integrative medicine. 2011; 9(7): 746-751.
  14. Itokawa H, Qiao Y, Takeya K. Anthraquinones and naphthohydroquinone from Rubiacordifolia. Phytochemistry. 1989; 28(12): 3465-3468.
  15. Rao GMM, Rao CV, Pushpangadan P, Shirwaikar A. Hepatoprotective effects of rubiadin, a major constituent of Rubiacordifolia Linn. Journal of Ethnopharmacology. 2006; 103(3): 484-490.
  16. Li X, Liu Z, Chen Y, Wang LJ, Zheng YN, Sun GZ and Ruan CC. Rubiacordone A: A new anthraquinones glycoside from the roots of Rubiacordifolia. Molecules.2009; 14: 566-572.
  17. Chang LC, Chavez D, Gills JJ, Fong HHS, Pezzuto JM, Kinghorn AD. Rubiasins A-C, new anthracene derivatives from the roots and stems of Rubiacordifolia. Tetrahedron Lett. 2000; 41(37): 7157- 7162.
  18. Arisawa M, Ueno H, Nimura M, Hayashi T, Morita N. Rubiatriol, a new triterpenoid from the Chinese drug “Qian Cao Gen,” Rubiacordifolia. Journal of Natural Products. 1986; 49(6): 1114-1116.
  19. Wu LJ, Wang SX, Hua HM, Li X, Zhu TR, Miyase T, Ueno A. 6-methoxygeniposidic acid, an iridoid glycoside from Rubiacordifolia. Phytochemistry. 1991; 30(5): 1710-1711.
  20. Talapatra SK, Sarkar AC, Talapatra B. Two pentacyclictriterpenes from Rubiacordifolia.Phytochemistry. 1981; 20(8): 1923-1927.
  21. Gupta PP, Srimal RC, Verma N, Tandon JS. Biological activity of rubiacordifolia and isolation of an active principle.Pharmaceutical Biology. 1999; 37(1): 46-49.
  22. Thomas J, Townsend JH, Hackney S, Strlic M. A chemiluminescence study of madder lakes on paper.Polymer Degradation and Stability.2010; 95: 2343- 2349.
  23. Hua HM, Wang SX, Wu LJ, Li X, Zhu TR. Studies on naphthoic acid esters from the roots of rubiacordifolia L. Yao XueXueBao. 1992; 27(4): 279- 282.
  24. Miyazawa M, Kawata J. Identification of the key aroma compounds in dried roots of Rubiacordifolia. J Oleo Sci. 2006; 55(1): 37-39.
  25. Kaur P, Chandel M, Kumar S, Kumar N, Singh B, Kaur S. Modulatory role of alizarin from Rubiacordifolia L. against genotoxicity of mutagens. Food and chemical toxicology.2010; 48: 320-325.
  26. Jun DY, Han CR, Choi MS, Bae MA, Woo MH, Kim YH. Effect of mollugin on apoptosis and adipogenesis of 3T3-L1 preadipocytes.Phytotherapy Research. 2011; 25: 724-731.
  27. Chung MI, Jou SJ, Cheng TH, Lin CN, Ko FN, Teng CM. Antiplatelet constituents of formosanRubiaakane. Journal of Natural Products. 1994; 57(2): 313-316.
  28. Kaur P, Kaur S, Kumar S, Singh P. Rubiacordifolia L. and Glycyrrhizaglabra L. medicinal plants as potential source of COX-2 inhibitors. Am J Biomed Sci. 2010; 2(2): 108-120.
  29. Kato T, Suzumura Y, Takamoto S, Ota K. Antitumor activity and toxicity in mice of RA-700, a cyclic hexapeptide. Anticancer Res. 1987; 7(3): 329-334.
  30. Morita H, Yamamiya T, Takeya K, Itokawa H. New antitumor bicyclic hexapeptides, RA-XI, -XII, -XIII and -XIV from Rubiacordifolia.Chem Pharm Bull. 1992; 40(5): 1352-1354.
  31. Ghosh S, Sarma MD, Patra A, Hazra B. Antiinflammatory and anticancer compounds isolated from VentilagomadraspatanaGaertn.,Rubiacordifolia L. and Lantana camara L. Journal of Pharmacy and Pharmacology. 2010; 62: 1158- 1166.
  32. Chitra V, Pavan KK. Neuroprotective studies of Rubiacordifolia Linn. on beta-amyloid induced cognitive dysfunction in mice. Int J Pharm Tech Res. 2009; 1(4): 1000-1009.
  33. Viswanathaswamy AHM, Koti BC, Singh AK, and Thippeswamy AHM.Antihyperglycemic and antihyperlipidemic effect of Rubiacordifolia leaf extract on alloxan induced diabetes. RGUHS Journal of Pharmaceutical Sciences. 2011; 1(1): 49- 52.
  34. Patel PR, Nagar AA, Patel RC, Rathod DK, Patel VR. In vitro anticancer activity of rubiacordifolia against HeLa and HEp-2 cell lines.Int J Pharm Pharm Sci. 2011; 3(2): 70-71.
  35. Deoda RS, Kumar D, Bhujbal SS, Yadav KN, Kadam PV, Patil MJ. Pharmacognostic and biological studies of the roots of Rubiacordifolia Linn.(Rubiaceae).Int J of Drug Dev& Res. 2011; 3(3): 148-158.
  36. Joharapurkar AA, Wanjari MM, Dixit PV, Zambad SP, Umathe SN. Pyrogallol: A novel tool for screening immunomodulators. Indian J Pharmacol. 2004; 36(6): 355-359.
  37. Joharapurkar AA, Zambad SP, Wanjari MM, Umathe SN. In vivo evaluation of antioxidant activity of alcoholic extract of Rubiacordifolia Linn.and its influence on ethanol induced immunosuppression. Indian J Pharmacol.2003; 35: 232-236.
  38. Divakar K, Pawar AT, Chandrasekhar SB, Dighe SB, DivakarGoli. Protective effect of the hydroalcoholic extract of Rubiacordifolia roots against ethylene glycol induced urolithiasis in rats. Food and Chemical Toxicology.2010; 48: 1013-1018.
  39. Joy J, Nair CK. Amelioration of cisplatin induced nephrotoxicity in swiss albino mice by Rubiacordifolia extract. J Cancer Res Ther. 2008; 4(3): 111-115.
  40. Pawar AT, Kalyani D, Chandrasekar SB, Divakar G. Diuretic activity of root extract of Rubiacordifolia. Pharmacologyonline 2009; 1: 597–603.
  41. Tailor CS, Bahuguna YM, Singh V. Antiinflammatory activity of ethanolic stem extracts of Rubiacordifolia L. in rats. International Journal of Research in Ayurveda and Pharmacy. 2010; 1(1): 126-130.
  42. Patil RA, Jagdale SC, Kasture SB. Antihyperglycemic, antistress and nootropic activity of roots of Rubiacordifolia Linn. Indian J Exp Biol. 2006; 44(12): 987-992.
  43. Gorle AM, Patil SS. Evaluation of antioxidant and antiacne property of Rubiacordifolia. Der Pharmacia Sinica. 2010; 1(3): 59-63.
  44. Pawar AT, Anap RM, Ghodasara JV, Kuchekar BS. Protective effect of hydroalcoholic root extract of Rubiacordifolia in Indomethacin induced enterocolitis in rats. Indian J Pharm Sci. 2011; 73(2): 250-253.
  45. Basu S, Ghosh A, Hazra B. Evaluation of the antibacterial activity of VentilagomadraspatanaGaertn.,Rubiacordifolia Linn. and Lantana camara Linn.: Isolation of Emodin and Physcion as active antibacterial agents. Phytotherapy research.2005; 19: 888-894.
  46. Ho LK, Don MJ, Chen HC, Yeh SF, Chen JM. Inhibition of Hepatitis B Surface Antigen Secretion on Human Hepatoma Cells.Components from Rubiacordifolia.J Nat Prod.1996; 59: 330-333.
  47. Lee JH, Kim NW, Her E, Kim BK, Hwang KH, Choi DK, Lim BO, Han JW, Kim YM, Choi WS. Rubiae Radix suppresses the activation of mast cells through the inhibition of Syk kinase for anti-allergic activity. Journal of Pharmacy and Pharmacology.2006; 58: 503-512.
  48. Tripathi YB, Pandey S, Shukla SD. Anti-platelet activating factor property of Rubiacordifolia. Indian J Exp Biol. 1993; 31(6): 533-535.
  49. Sawhney R, Berry V, Kumar A. Inhibitory activity of Rubiacordifolia plant extract against ESBL producing urinary E.coli isolates. Journal of Pharmacy Research. 2012; 5(3): 1328-1330.
  50. Shilpa PN, Venkatabalasubramanian S, Devaraj SN. Ameliorative effect of methanol extract of Rubiacordifolia in N-nitrosodiethylamine-induced hepatocellular carcinoma.Pharmaceutical Biology. 2012; 50(3): 376-383.
  51. Zhou LL, Lin ZX, Fung KP, Che CT, Zhao M, Cheng CHK, Zuo Z. Ethyl acetate fraction of Radix rubiae inhibits cell growth and promotes terminal differentiation in cultured human keratinocytes. Journal of Ethnopharmacology.2012; 142: 241-247.
  52. Shilpa PN, Venkatabalasubramanian S, Devaraj SN. Induction of Apoptosis by methanolic extract of Rubiacordifolia L. in HEp-2 cell line is mediated by reactive oxygen species. Asian Pacific Journal of Cancer Prevention.2012; 12: 2753-2758.
  53. Fotia C, Avnet S, Granchi D, Baldini N. The natural compound alizarin as an osteotropic drug for the treatment of bone tumors.J Orthop Res. 2012; 30: 1486-1492.
  54. Gilani AH, Janbaz KH, Zaman M, Lateef A, Suria A, Ahmed HR. Possible presence of calcium channel blocker(s) in Rubiacordifolia: an indigenous medicinal plant. J Pak Med Assoc. 1994; 44(4): 82- 85.